NEW YORK, Nov. 21, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Array Biopharma, Inc.("Array" or the "Company") (Nasdaq: ARRY). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/arry.

The investigation concerns whether Array and certain of its officers and/or directors have violated Federal Securities Laws.

On March 19, 2017, Array issued a press release announcing the withdrawal of the New Drug Application ("NDA") for the Company's cancer drug binimetinib, stating that "based on feedback from the [U.S. Food and Drug Administration], Array concluded that the clinical benefit demonstrated in [a recent Phase 3 clinical trial] would not be found sufficient to support approval" of the NDA. On this news, Array's share price fell $1.43, or 13.5%, over the following two trading days, to close at $9.13 on March 21, 2017.

If you are aware of any facts relating to this investigation, or purchased Array shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/arry. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

View original content with multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-array-biopharma-inc-arry-300560495.html

SOURCE Bronstein, Gewirtz & Grossman, LLC